Modified-release recombinant human TSH (MRrhTSH) augments the effect of (131)I therapy in benign multinodular goiter: results from a multicenter international, randomized, placebo-controlled study

H Graf, S Fast, F Pacini, A Pinchera, A Leung, M Vaisman, C Reiners, J L Wemeau, D Huysmans, Willie F. Harper, A Driedger, H Noemberg de Souza, M G Castagna, L Antonangeli, L Braverman, R Corbo, C Düren, E Proust-Lemoine, M A Edelbroek, C MarriottI Rachinsky, Peter Grupe, T Watt, J Magner, L Hegedus

    44 Citationer (Scopus)

    Abstract

    Recombinant human TSH (rhTSH) can be used to enhance (131)I therapy for shrinkage of multinodular goiter (MG). OBJECTIVE, DESIGN, AND SETTING: The objective of the study was to compare the efficacy and safety of 0.01 and 0.03 mg modified-release (MR) rhTSH as an adjuvant to (131)I therapy, vs. (131)I alone, in a randomized, placebo-controlled, international, multicenter study.
    OriginalsprogEngelsk
    TidsskriftJournal of Clinical Endocrinology and Metabolism
    Vol/bind96
    Udgave nummer5
    Sider (fra-til)1368-76
    Antal sider9
    ISSN0021-972X
    DOI
    StatusUdgivet - 2011

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Modified-release recombinant human TSH (MRrhTSH) augments the effect of (131)I therapy in benign multinodular goiter: results from a multicenter international, randomized, placebo-controlled study'. Sammen danner de et unikt fingeraftryk.

    Citationsformater